Beijing Bulin Biotechnology

Beijing Bulin Biotechnology (Bulin Bio) is an innovative biotechnology company based in Beijing, China, dedicated to the discovery and development of next-generation therapeutic antibodies. Founded in 2021, the company utilizes a proprietary high-throughput single-cell sequencing and functional screening platform to rapidly identify high-affinity, fully human antibodies directly from primary B cells. Bulin Bio's technology platform integrates microfluidics, genomics, and bioinformatics to overcome challenges in targeting complex proteins, including GPCRs and ion channels. The company's internal pipeline includes several pre-clinical programs targeting validated and novel pathways in oncology, such as Claudin 18.2, PD-L1, CD3, and TIGIT. Bulin Bio aims to address unmet medical needs by accelerating the transition from target identification to clinical candidates for cancer and autoimmune diseases. The company has attracted significant investment from leading venture capital firms, including Legend Capital and CasStar, to support its internal pipeline and technology advancement.